FDA Approves First Generic Twice-Yearly HIV Prevention Shot for Developing Nations

The U.S. Food and Drug Administration has granted tentative approval to the first generic version of lenacapavir, a highly effective twice-yearly injection for HIV prevention. The milestone clears a major regulatory hurdle to distribute the drug in 120 low- and middle-income countries, where the burden of new infections remains highest.[1][2]

The generic, manufactured by India-based Dr. Reddy's Laboratories, received the green light just 16 months after Gilead Sciences secured approval for the originator product in June 2025. The rapid turnaround was facilitated by the FDA's President's Emergency Plan for AIDS Relief (PEPFAR) program, which allows the agency to vet drugs for international donor purchase even if they cannot be sold domestically.[2][3]

"Getting a generic approved just 16 months after the originator, rather than a decade later, shows what's possible when we prioritize access from the start," said Dr. Neil Buddy Shah, CEO of the Clinton Health Access Initiative (CHAI). "This should be the new standard for global health."[1][4]

For individuals at high risk of contracting HIV, lenacapavir represents a paradigm shift in pre-exposure prophylaxis (PrEP). Instead of requiring a daily oral pill—a regimen that often suffers from adherence challenges, particularly among young women and marginalized populations—the long-acting injection provides near-total protection with just two doses per year.[1][5]

Lenacapavir is a first-in-class capsid inhibitor that interferes with multiple essential steps of the viral lifecycle. By disrupting the HIV capsid, the protein shell that protects the virus's genetic material, the drug prevents the virus from multiplying and establishing an infection in the body.[5]

A $40 Annual Regimen

Under a non-exclusive, royalty-free voluntary licensing agreement signed with Gilead in late 2024, Dr. Reddy's will produce the generic for $40 per person per year. In the United States, Gilead's branded version, marketed as Yeztugo, carries a list price of more than $28,000 annually.[1][4][5]

The $40 price point intentionally aligns with the current cost of daily oral PrEP, removing a major financial barrier for health ministries in developing nations. More than 125,000 people in 10 early-adopter African countries have already begun receiving lenacapavir, and the generic approval is expected to expand that access to millions.[1][4]

The accelerated timeline was driven by a September 2025 partnership between Dr. Reddy's, Unitaid, CHAI, and the Wits Reproductive Health and HIV Institute (Wits RHI). The coalition provided financial, technical, and regulatory support to expedite the generic's development and market entry.[2][3][4]

To speed up the process, Dr. Reddy's utilized the FDA's 505(b)(2) regulatory pathway, combining lenacapavir's indications for both HIV prevention and HIV treatment into a single application. This strategy allowed the manufacturer to request and secure a priority review from the agency, shaving years off the typical generic approval timeline.[4]

Tentative FDA approval means the generic meets all safety, efficacy, and manufacturing quality standards but cannot be sold in the United States while the originator remains under patent. However, the designation makes the product immediately eligible for purchase by the U.S. government and international procurement agencies for global distribution.[2][3]

Manufacturing and Regulatory Hurdles

Producing a long-acting injectable is significantly more complex than manufacturing standard oral tablets. The formulation requires precise engineering to ensure the active pharmaceutical ingredient is released slowly and consistently into the bloodstream over a six-month period.[1]

Dr. Reddy's CEO of API and Services, Deepak Sapra, called the approval a moment of immense pride. "Developing and manufacturing a complex long-acting injectable like lenacapavir at an affordable price required strong scientific capabilities and manufacturing expertise to address an urgent access need," Sapra said.[1][2]

The FDA's tentative approval provides a critical regulatory foundation for the remaining steps toward wider availability. The dossier will now be submitted for World Health Organization (WHO) prequalification, a stamp of approval that guides procurement decisions for the Global Fund and other major international health financiers.[2]

Simultaneously, Dr. Reddy's must secure national regulatory approvals in each of the 120 eligible countries. While some nations rely heavily on FDA or WHO decisions to fast-track their own authorizations, others require localized clinical data or independent reviews, which can delay access.[2][4]

Rollout and Health System Readiness

Initial supplies of the generic injection are expected to reach early-adopter countries, including Zambia, by the end of 2026. A broader rollout across the 120 eligible nations is scheduled for 2027, assuming the necessary regulatory and procurement hurdles are cleared.[1][2][3]

While the $40 price point solves the procurement challenge, public health experts caution that affordability is only the first step. Delivering a twice-yearly injection at a population scale requires robust clinical infrastructure, reliable supply chains, and trained healthcare personnel.[1][4]

"Generic lenacapavir has the potential to transform HIV prevention, and this is a significant milestone, but an affordable drug alone is not enough," said Professor Saiqa Mullick, director of implementation science at Wits RHI. "Countries need health systems that are ready to deliver new prevention options."[1][4]

Mullick emphasized that providers must be confident in offering the injections, and communities must be engaged as partners in the scale-up. Stigma surrounding HIV prevention remains a significant barrier in many regions, and educational campaigns will be necessary to drive uptake.[1][4]

Unitaid, CHAI, and Wits RHI are currently coordinating with national governments, the Global Fund, the U.S. Bureau of Global Health Security and Diplomacy, and the Gates Foundation to prepare for the rollout. The coalition plans to collect real-world data on reaching underserved populations during the initial distribution phase.[4]

The success of this rapid generic introduction could serve as a blueprint for future global health interventions. By prioritizing access agreements and regulatory support before the originator drug even hit the market, the coalition demonstrated that the traditional decade-long wait for affordable generics is not inevitable.[1][4]